A5020816857- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Venous Thromboembolism Diagnosis and Management
- Childhood Cancer Survivors' Quality of Life
- Central Venous Catheters and Hemodialysis
- Family Support in Illness
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Adolescent and Pediatric Healthcare
- Nursing Education, Practice, and Leadership
- Peptidase Inhibition and Analysis
- Extracellular vesicles in disease
- Glioma Diagnosis and Treatment
- Sepsis Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Adenosine and Purinergic Signaling
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Primary Care and Health Outcomes
- MicroRNA in disease regulation
- Patient Dignity and Privacy
- Heparin-Induced Thrombocytopenia and Thrombosis
Memorial University of Newfoundland
2014-2024
Janeway Children's Health and Rehabilitation Centre
2014-2024
Brunswick (United States)
2023
St. John's School
2013-2021
Eastern Health
2021
Faculty (United Kingdom)
2019
St. John’s Health Sciences Centre
2018
Baxter (United States)
2014
Biogen (United States)
2014
Pfizer (United States)
2014
Objective Individuals with deficiency of adenosine deaminase 2 ( DADA 2), a recently recognized autosomal recessive disease, present various systemic vascular and inflammatory manifestations, often young age at disease onset or early recurrent strokes. Their clinical features histologic findings overlap those childhood‐onset polyarteritis nodosa PAN ), primary “idiopathic” vasculitis. Despite similar presentation, individuals may respond better to biologic therapy than traditional...
Background: Pediatric pulmonary embolism (PE) is a rare event associated with significant morbidity and mortality.Awareness of clinical presentation practices unique to children may aid clinicians in prompt identification treatment.Objectives: To describe the incidence, risk factors, presentation, diagnostic therapeutic practices, short-term outcomes pediatric PE.Methods: We conducted 3-year national surveillance study through Canadian Surveillance Program.Over 2,800 specialists...
Abstract Objective Our objective was to generate, optimize, and validate a self‐administered pediatric bleeding questionnaire (Self‐PBQ) as screening tool for von Willebrand disease (VWD) in children referred the hematology clinic first time. Study Design The Self‐PBQ generated by combining validated expert‐administered PBQ International Society on Thrombosis Hemostasis (ISTH) assessment (BAT). Medical terminology translated into lay language requiring grade 4 reading level. In Phase 1,...
The need for new therapies to improve survival and outcomes in pediatric oncology along with the lack of approval accessible clinical trials has led "out-of-trial" use innovative therapies. We conducted a retrospective analysis requests anticancer therapy Canadian tertiary centers patients less than 30 years old between 2013 2020.
Edited by Ronald Labonté, Vivien Runnels, Corinne Packer and Raywat Deonandan (University of Ottawa) . Imagine leaving your own country to buy a surgery or an organ even pregnancy. The personal enormity such actions seems at odds with the frivolous term used describe them: medical
There are no proven methods to predict the risk of clinically significant bleeding in PICU. A retrospective study identified platelet count as a marker for bleeding. We conducted examine any association count, international normalized ratio, and activated partial thromboplastin time with PICU patients.Prospective observational cohort study.The at Children's Hospital Eastern Ontario, university-affiliated tertiary care pediatric center.Consecutive patients admitted Exclusion criteria were...
The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication hemophilia A treatment. sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune induction (ITI) which expensive, difficult administer and not always successful. Although fully understood, the mechanism ITI thought rely on inhibition FVIII-specific B cells (1). Its efficacy might therefore be improved through more aggressive cell suppression. FcγRIIB...
The development of inhibitory antibodies to factor VIII is the most serious complication replacement therapy in hemophilia A. Activation innate immune system during exposure this protein contributes inhibitor development. However, avoidance activation by external stimuli (e.g., vaccines) has not been consistently shown prevent inhibitors. We hypothesized that dexamethasone, a drug with potent anti-inflammatory effects, could inhibitors promoting immunologic tolerance A mice. Transient...
With significant improvements in the survival rates for most childhood cancers, there is increased pressure to determine how follow-up or aftercare survivors best structured.Previous work this area has not been consistent it categorizes models of aftercare, which risks confusion between studies and evaluations different models. The adoption a standardized method classifying describing necessary order maximize applicability available evidence. We identify some ways have classified previous...
<h3>Background:</h3> Childhood cancer survivors (CCSs) face increased risks during the period when they leave pediatric care and transition into adult-focused aftercare. We examined experiences of CCSs entering aftercare to gain a better understanding current practices barriers transition, identify opportunities for improving care. <h3>Methods:</h3> conducted qualitative study using in-person telephone semi-structured interviews. who recently transitioned out health providers (HCPs) provide...
Tommy Douglas. Vincent Lam. Penguin Canada, Extraordinary Canadians series; 2011 The typical biographer either sharpens his subject’s horns or polishes halo. (A third option — mundane agnosticism is rarely attempted.) Toronto emergency physician Lam reveals choice early in
To determine the epidemiology and identify risk factors for clinically significant bleeding in pediatric intensive care unit.A retrospective cohort study over 6 months with up to 7 days of observation each patient.The unit a tertiary children's hospital.Three hundred twenty-six consecutive patients admitted during period, 214 eligible inclusion.Clinically bleeding, defined using composite outcomes. Clinically occurred 19 (8.9%). Recursive partitioning identified platelet count <100 × 10/L as...
We report an 11-month-old boy with severe hemophilia A who had regular exposure to factor VIII (FVIII) intended reduce the risk of developing inhibitor. He developed a high-titer inhibitor (peak titer 19 BU) that disappeared within 6 weeks starting immune tolerance induction (ITI). Anti-FVIII IgG4 peaked briefly compared anti-FVIII IgG1 and Bethesda titer. Neither rapid resolution after prophylaxis nor this behavior has been previously reported. Transient may be marker attenuated response...